Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 4/20 | 0.37 |
| ▸ | CNR1 | P21554 | 3/20 | 0.37 |
| ▸ | FABP4 | P15090 | 5/20 | 0.35 |
| ▸ | FABP5 | Q01469 | 5/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.31 |
| ▸ | RORC | P51449 | 1/20 | 0.30 |
| ▸ | CCR5 | P51681 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21247149 | 0.85 | CNR1 (0.43) | CNR2CNR1FABP4FABP5 | |
| SCHEMBL22680854 | 0.80 | CXCR2 (0.34) | PTPN1RORC | |
| SCHEMBL21261122 | 0.79 | PTPN1 (0.47) | PTPN1RORC | |
| SCHEMBL21261121 | 0.76 | CNR2 (0.36) | CNR2CNR1FABP4FABP5 | |
| SCHEMBL22680797 | 0.74 | NOD1 (0.42) | CNR2CNR1 | |
| SCHEMBL21247099 | 0.71 | RAB7A (0.56) | FABP4FABP5 | |
| SCHEMBL21247146 | 0.67 | LMNA (0.47) | — | |
| SCHEMBL21260935 | 0.67 | CNR2 (0.43) | CNR2CNR1FABP4FABP5PTPN1 | |
| SCHEMBL21253132 | 0.66 | RAB9A (0.58) | CNR2CNR1 | |
| SCHEMBL21247283 | 0.64 | TNF (0.61) | CNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200361924-A1 | FUSED THIOPHENE DERIVATIVES AND THEIR USES | ENYO PHARMA (FR) | 2020-11-19 | — | — | US | disclosed |
| WO-2019154950-A1 | FUSED THIOPHENE DERIVATIVES AND THEIR USES | ENYO PHARMA (FR) | 2019-08-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200361924-A1 | FUSED THIOPHENE DERIVATIVES AND THEIR USES | FTH1, SLC40A1, FECH | CNR2 4405/4885CNR1 4561/4885FABP4 331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.